|File:Odanacatib Structural Formulae V.1.svg|
|Systematic (IUPAC) name|
|14px (what is this?)|
It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. It is expected Merck will apply for approval by late-2014. Cowen and Co predicted it will bring a billion a year in sales by 2020.
This drug was developed at Merck Frosst in Montreal.
- Le Gall, C. L.; Bonnelye, E.; Clézardin, P. (2008). "Cathepsin K inhibitors as treatment of bone metastasis". Current Opinion in Supportive and Palliative Care 2 (3): 218–22. PMID 18685424. doi:10.1097/SPC.0b013e32830baea9.
- Gauthier JY, Chauret N, Cromlish W et al. (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. PMID 18226527. doi:10.1016/j.bmcl.2007.12.047.
- "Merck to seek approval of osteoporosis drug, cites safety risks". Reuters. 2014-05-06.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.